Prostatype Genomics AB (OSTO:PROGEN) Net Income (Continuing Operations): kr-44.50 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
23 GF Score
Price kr0.15
GF Value kr0.04
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Net Income (Continuing Operations)?

Prostatype Genomics AB OSTO:PROGEN -5.38% 23 Net Income (Continuing Operations) is kr-44.50 Mil as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Prostatype Genomics AB's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was kr-20.58 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-44.50 Mil.

Prostatype Genomics AB  (OSTO:PROGEN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Prostatype Genomics AB Net Income (Continuing Operations) Related Terms

Prostatype Genomics AB Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Net Income (Continuing Operations) Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -15.63 -29.09 -41.44 -41.05 -44.50

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.88 -19.67 -21.39 -23.92 -20.58
OSTO:PROGEN
23GF Score
Prostatype Genomics AB OSTO:PROGEN
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-44.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of kr-44.50 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Net Income (Continuing Operations) of kr-44.50 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Net Income (Continuing Operations) too high?
Prostatype Genomics AB's current Net Income (Continuing Operations) is kr-44.50 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Net Income (Continuing Operations) compare to TMO and DHR?
Prostatype Genomics AB's Net Income (Continuing Operations) of kr-44.50 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Diagnostics & Research company?
A good Net Income (Continuing Operations) depends on the Medical Diagnostics & Research industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Net Income (Continuing Operations) is kr-44.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.15 — trading 273.8% above its estimated fair value. The current Net Income (Continuing Operations) is kr-44.50 Mil. Prostatype Genomics AB's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Net Income (Continuing Operations) is kr-44.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.15 is trading 273.8% above its estimated GF Value™ of kr0.04. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Net Income (Continuing Operations): kr-44.50 Mil
  • GF Value™: kr0.04 vs. price of kr0.15 (273.8% above fair value)
  • GF Score™: 23/100 with 6 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Other Exchanges PGO0:Germany
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score

Get the complete analysis for OSTO:PROGEN

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.15
Price
kr0.04
GF Value